Serotonin in Impulse Control Disorders in Parkinson's Disease
Status:
Recruiting
Trial end date:
2022-02-13
Target enrollment:
Participant gender:
Summary
Impulse control disorders are frequent and troublesome in patients with Parkinson's disease.
However, the cerebral functional alterations related to impulse control disorders in
Parkinson's disease are poorly understood and may involve the serotoninergic system besides
alterations in the dopaminergic system.
The primary objective of this study is to investigate the cerebral functional alterations in
the serotoninergic system in patients with Parkinson's disease and impulse control disorders
using Positron Emission Tomography with highly specific radiotracers of serotonin transporter
(SERT) using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile
([11C]-DASB) and of serotonin 5-Hydroxytryptamine 2A (5-HT2A) receptor using [18
Fluorine]-altanserin ([18F]-altanserin), in comparison to patients with Parkinson's disease
without impulse control disorders and healthy volunteers.